Emmaus Life Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

SELECTED FINANCIAL STATEMENT - ASSETS

SELECTED FINANCIAL STATEMENT - ASSETS

9 Months Ended

Sep. 30, 2023

Balance Sheet Related Disclosures [Abstract]

SELECTED FINANCIAL STATEMENT - ASSETS

NOTE 4 — SELECTED FINANCIAL STATEMENT — ASSETS

Inventories consisted of the following (in thousands):


	September 30, 2023			December 31, 2022
Raw materials and components	$	1,362		$	1,393
Work-in-process		228			513
Finished goods		5,100			5,428
Inventory reserve		(5,040	)		(4,955	)
Total inventories, net	$	1,650		$	2,379

Prepaid expenses and other current assets consisted of the following (in thousands):


	September 30, 2023		December 31, 2022
Prepaid insurance	$	132	$	598
Prepaid expenses		736		467
Other current assets		647		449
Total prepaid expenses and other current assets	$	1,515	$	1,514

Property and equipment consisted of the following (in thousands):


	September 30, 2023			December 31, 2022
Equipment	$	377		$	367
Leasehold improvements		39			39
Furniture and fixtures		99			99
Total property and equipment		515			505
Less: accumulated depreciation		(455	)		(430	)
Total property and equipment, net	$	60		$	75

During the three months ended September 30, 2023 and 2022, depreciation expense was approximately $7,000 and $9,000, respectively. During the nine months ended September 30, 2023 and 2022, depreciation expense was approximately $26,000 and $30,000, respectively.